Mechanistic Insights and Advances of Bispecific T Cell Engaging Antibodies Therapy in Multiple Myeloma.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology
PubMed 41470115 · doi:10.3390/medicina61122113
What was done
This narrative review summarizes the molecular design, mechanism of action, and clinical development of bispecific T cell engaging antibodies (TCEs) targeting tumor-associated antigens (BCMA, GPRC5D, FcRH5) and CD3 in multiple myeloma, spanning early BiTE constructs (AMG 420) to IgG-like molecules (teclistamab).
What was found
Pivotal clinical trials cited in the review demonstrated overall response rates between 43% and 73%, with durable remissions and manageable safety profiles. Exact participant counts and individual trial statistics are not specified in the abstract.
Why it matters
TCEs offer an active immunotherapy mechanism to direct cytotoxic T cells against malignant plasma cells, providing therapeutic options for patients with heavily pretreated or triple-class-refractory multiple myeloma.
Limits
The paper is a narrative review rather than a systematic review or meta-analysis. The abstract provides no specific patient numbers, comparative controls, granular survival statistics, or detailed toxicity data.
Cited by
- supports Bispecific T-cell engagers (BiTEs) are dual-binding antibodies designed to simultaneously bind a target on a cancer cell and a target on a T cell, directing endogenous T cells to kill the cancer cell without requiring genetic modification of the T cells.